向放射性核素治疗对癌细胞的影响超出了废弃辐射剂量
Guillermina Ferro-Flores1, Erika Azorín-Vega1, Blanca Ocampo-García1
1Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.
International journal of molecular sciences
|July 29, 2025
概括
向放射性核酸治疗 (TRT) 使用放射性药物治疗癌症. 通过直接杀死细胞和非向效应 (NTEs),TRT提高了疗效,改善了患者的治疗结果.
科学领域:
- 在瘤学瘤学.
- 放射性药物疗法是一种放射性药物疗法.
- 癌症生物学 癌症生物学
背景情况:
- 向放射性核酸治疗 (TRT) 直接向癌细胞输送辐射.
- TRT的疗效由非向效应 (NTEs) 增强,包括旁观者和非眼效应.
- TRT 影响瘤微环境,调节免疫反应.
研究的目的:
- 审查TRT的双重机制:直接毒性和NTEs.
- 讨论提高TRT疗效和扩大其临床应用的策略.
- 为个性化的TRT.突出了theranostics和人工智能的进步.
主要方法:
- 审查关于TRT机制和临床结果的现有文献.
- 对TRT涉及的分子通路的分析,包括DNA损伤和修复.
- 检查在TRT研究中的挑战和未来方向.
主要成果:
- TRT诱导直接癌细胞死亡和有益的NTE.
- 分子机制包括DNA损伤,氧化应激和亡.
- 治疗神经学和人工智能的进步为治疗优化提供了潜力.
结论:
- TRT提供了显著的生存益处,但面临着放射电阻等挑战.
- 了解NTE和分子途径对于改善TRT至关重要.
- 个性化方法和组合疗法是扩大TRT在瘤学中的作用的关键.
更多相关视频
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Tumor Immunotherapy
662
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
662
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Cancer Therapies
8.0K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.0K


